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1. Introduction 
 
 
1.1 Chronic Myeloid Leukaemia 
 
Chronic myeloid leukaemia (CML) is a clonal myelo-proliferative disorder of the 
hematopoietic stem cell (1). It is a neoplastic disease characterized by the increased and 
unregulated growth of white blood cells in spleen, liver, peripheral blood and, more rarely, 
in the lymph nodes. CML it is also characterized by an impairment of the granulocytic 
lineage in their capacity to differentiate. Consequently, the peripheral blood cell profile 
shows an increased number of granulocytes and their immature precursors, including 
occasional blast cells (2,3). 
Incidence of CML is rare, about 1 o 2 cases per 100.000 people every year, with a 
prevalence in older people as median age at diagnosis is about 50 years.  
Men are affected more frequently than women, although female patients seem to have a 
survival advantage. No obvious geographical or ethnic differences exist, but differences in 
management strategies between countries could be dependent on the availability of 
expensive drugs and modern diagnostic technologies (4).  
Diagnosis of CML is generally straightforward. In most cases the diagnosis is made on the 
basis of the characteristic blood count (white blood cells count > 25.000/µL) and upon 
exclusion of myelofibrosis or myelodysplasia. 
CML typically evolves in three distinct clinical stages: chronic phase, accelerate phase, 
and blast crisis. The chronic, or stable, phase lasts several years and is characterized by 
an excessive number of myeloid precursors and mature cells in bone marrow, peripheral 
blood and extra-medullary sites (1,5). The accelerate phase last 4 to 6 months and is 
characterized by an increase in disease burden and in the percentage of 
progenitor/precursor cell that are detected in the peripheral blood.  
Historically, within an average of 4 to 6 years, the disease evolves from accelerate phase 
to an, invariably fatal, acute disease, also known as blast crisis. This crisis last only a few 
months and is characterized by the rapid expansion of a population of myeloid or lymphoid 
blasts (1,5,6). 
From a patho-physiological point of view, the immediate cause of CML was discovered in 
1960 by Nowell and Hugerford, who described the presence of a small acrocentric 
chromosome, named Philadelphia chromosome (Ph) after the hometown of its discovery, 
in blood cells isolated from patients with CML (6). In 1973, Rowley showed that this 
abnormal Ph chromosome was a result of a reciprocal translocation between the long 
arms of chromosome 9 and 22 t(9;22)(q34;q11). In details, it was shown that a long arm of 
the abelson (abl) gene, located on chromosome 9, is translocated to the breakpoint cluster 
region (bcr) gene on chromosome 22 (Figure 1).  
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This translocation generates the bcr-abl fusion gene, which is translated, in the majority of 
the patients with CML, in a 210kDa protein indicated as p210BCR-ABL (1,6). Expression of 
p210BCR-ABL has been shown to be necessary and sufficient for the malignant 
transformation of of CML blood cells (1, 2). 
Alternatively, other two BCR-ABL proteins may be generated, depending on the region of 
the breakpoint on the bcr gene, although these are detected in classic CML only 
occasionally.  
BCR-ABL, unlike the normal p145 c-Abl, is predominantly localized in the cytoplasm and 
has constitutive tyrosine kinase activity, essential for cell transformation. The cytoplasmic 
localization of the oncoprotein allows the assembly of phopshorylated substrates in 
multiprotein complexes that transduce mitogenic and antiapoptotic signals (1).  
Ectopic expression of BCR-ABL in growth factor-dependent cell lines activates numerous 
signal transduction pathways responsible for acquisition of growth factor independence 
and reduced susceptibility to apoptosis. For instance, it is known from literature that the 
ectopic expression of BCR-ABL enables phosphatidylinositol-3 kinase (PI-3K)-dependent 
activation of Akt. This cascade of events plays a critical role in BCR-ABL-driven 
transformation since it regulates the subcellular localization or activity of several effectors 
with relevance in cell proliferation and viability, such as: BAD, MDM2, IkB-kinase-α and 
members of the Forkhead family of transcription factors.  
It is also assumed that, BCR-ABL supports cell proliferations by reducing the nuclear 
localization of p27KIP and increasing the expression of Cdk2.  
On the other hand, BCR-ABL may induce leukeamogenesis also stabilizing cyclin D1 and 
β-catenin, through the inactivation of GSK-3β (7). 
Figure 1. Schematic diagram of the translocation that 
creates the Philadelphia chromosome 
  
The abl and bcr genes reside on the long arms 
respectively of chromosome 9 and 22. bcr-abl gene is 
formed on the derivative chromosome 22 (Philadelphia 
chromosome), as result of the (9:22) translocation. 
Illustration by Druker Brian J., Blood, 2008 December; 
112 (13); 4808-4814. 
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Nonethelss, BCR-ABL-dependent activation of STAT5 probably represents the most 
critical event for the maintenance of CML, since the direct phosphorylation of this protein 
enables its transcriptional program toward transformation (Figure 2).  
 
 
 
 
 
 
 
 
 
 
1.2 CML Therapy 
 
Before the discovery of Tyrosine Kinase Inibhitor (TKI) class of drugs, the conventional 
treatments for CML were based on the use of cytotoxic chemotherapies, in particular 
busulfan and hydroxyurea. Later, in 1980, allogenic stem cell transplantation became the 
only curative treatment for CML, although this therapeutic option is accessible to a limited 
number of patients due to difficulties in enrolling suitable donors (6). Also in the 80s, 
interferon alpha was introduced to treat patients ineligible for transplant, progressively 
replacing both busulfan and hydroxyurea in the management of CML for improved survival 
and durable cytogenetic responses, in approximately one-third of the patients (8). In 1998, 
CML therapy was revolutionized by the introduction on the market of the first TKI, imatinib 
(Gleevec®; Figure 3).  
Imatinib is a small molecule that targets the BCR-ABL tyrosine kinase by competitively 
inhibiting the binding of adenosine triphosphate (ATP) to the catalytic site of the ABL 
kinase. Subsequent studies, also showed that imatinib was able to inhibit other tyrosine 
kinases, in particular c-Kit and PDGFβ-R (Figure 4) (7). 
Figure 2. Signaling pathways 
impacted by BCR-ABL 
expression 
 
Schematic representations of the 
main BCR-ABL activated 
pathways regulating survival and 
proliferation of BCR-ABL-
transformed hematopoietic cells. 
Note that is a simplified diagram. 
Illustration by Deininger Michael 
W. N., et al., Blood, 2000 
November; 112 (13): 3343-3356. 
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As regarded the treatment CML patients bearing the Ph chromosome, imatinib showed its 
high efficacy as evaluated in Phase I and II clinical trials; this caused an accelerated FDA 
approval, in May 2001, for treating Ph+ CML patients during blast crisis and accelerate 
phase, or those in chronic phase, after failure of treatment with Interferon-alpha. The 
development of these target therapies overcame the limitations of the previous 
conventional treatments; indeed imatinib demonstrated a good tolerability and superiority 
in terms of hematologic and cytogenetic responses, as compared to Interferon-alpha (4, 9). 
Although in most of the cases imatinib was able to control the chronic phase of CML, 
some patients relapsed, after a period of improvement, or progressed to accelerated 
phase or blast crisis.  
 
 
 
 
 
Although the mechanisms responsible for resistance to imatinib are still not completely 
known, it has been demonstrated that treatments with this compound may lead to 
selection of cells overexpressing BCR-ABL or expressing normal levels of BCR-ABL but 
with mutations in the ABL kinase domain, e.g. T315I and Y253H mutations (10,11). 
BCR-ABL-independent mechanisms are the second major category of resistance to 
imatinib. In particular, a decreased intake of imatinib or an eccessive efflux, as caused by 
the increased expression of P-glycoprotein (Pgp)(11), may be responsible for maintaining 
intracellular concentration of this drug just below the therapeutic level. 
Figure 3. Chemical structure of imatinib 
 
Illustration by www.theodora.com web site 
 
Illustration by Brian J. Druker, Blood, 2008 
December; 112 (13); 4808-4814. 
 
 
 
 
 
Figure 4. Mechanism of action of imatinib 
 
The constitutively active BCR-ABL tyrosine 
kinase function by transferring phosphate 
from ATP to tyrosine residues, that causes 
excess proliferation of myeloid cells in CML 
(left panel). 
Imatinib blocks the binding of ATP to BCR-
ABL, thus inhibiting the kinase activity of the 
protein (right panel). 
Illustration by Druker Brian J., Blood, 2008 
December; 112 (13): 4808-4814. 
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On the other hand, BCR-ABL-independent activation of signaling pathways such as 
Src/Ras/Raf/MEK/Lyn, STAT3/5, Wnt/β-catenin, FoxO and SIR1, which conceivably 
coexist in the same cell, may also play a role in CML resistance to therapies and 
progression of the disease (2,4,5).  
In order to overcome resistance to imatinib and improve the prognosis of patients with 
CML, second-generation inhibitors of BCR-ABL have been introduced on the market, such 
as dasatinib and nilotinib.  
Dasatinib is a piperazinyl derivate that potently targets also Src and Abl kinases as well as 
most of the mutated form BCR-ABL (with the exclusion of T315I).  
Nilotinib is an aminopyridine derivate that inhibits the tyrosine kinase activity of the 
unmutated and most mutated form of BCR-ABL, more potently and more selectively than 
imatinib, although sparing the T315I mutated oncoprotein. Consequently, Dasatinib and 
Nilotinib are highly effective in treating many but not all the cases of imatinib-resistant CML 
(9). As consequent to these aspects of TKI-resistance, allogeneic stem-cell transplantation 
is the only treatment that can lead to a complete cytogenetic remission, but often the main 
disadvantage of this therapy is associated to “graft vs host” reactions that, during 
treatment, can induce the death of approximately 30% of patients. 
 
Recently, investigations on the mechanisms that cause the escape of CML from cures 
unveiled the existence of a primitive sub-set of cells endowed with stem capacity, thus 
named leukaemic stem cells (LSCs). LSCs are the transformed counterpart of normal 
hematopoietic stem cells (HSCs), since they are equipped with very peculiar capacities 
such as: self-renewal (in supportive microenvironment) and quiescence, characterized by 
a lengthy G1 phase of the cell cycle and highly efficient DNA-repair response, that 
provides resistance to either canonical cytotoxic chemotherapies and “target therapies”, 
such TKI, directed towards fast proliferating cells. Indeed, the population of cells, which is 
involved in chronic phase initiation of CML, expresses surface markers that are in common 
with HSCs, i.e. CD34+CD38-CD90+Lin-, and partially preserve their ability to undergo a 
myeloid differentiation, thus leading to myeloid progenitor expansion. Upon shifting to the 
blast crisis stage of the disease, leukemia is fueled the expansion of the granulocyte-
macrophage progenitor (GMP) population, which presents an amplified BCR-ABL 
expression. The malignant GMPs are reprogrammed to regenerate via aberrant activation 
of self-renewal and survival pathways, determining the therapeutic resistance (12). 
This type of resistance may be a consequence of the genetic instability promoted, at least 
in part, by the activity of BCR-ABL on its own. Indeed, recent studies demonstrated that 
LSCs resistance to TKIs is not consequent to an altered binding of these drugs to BCR-
ABL but to an aberrant activation of additional signaling pathways, both intrinsic to LSCs 
and controlling their survival and self-renewal, or extrinsic to them, although capable to 
support the hematopoietic microenvironments (13). Indeed, cumulative research efforts 
brought to the demonstration that inactivation of apoptosis and induction of autophagy, 
through an interference on Wnt/β-catenin or glycogen synthase kinase-3β (GSK-3β) signal 
pathways, may be key cell-intrinsic factors that promote LSCs persistence and TKI 
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resistance. Adding to this, cell-extrinsic factors may sustain CML through production, by 
the hematopoietic microenvironments (bone marrow niche), of mediators that promote cell 
migration and protection of LSCs (Figure 5)(12).  
 
 
 
According to what described above, in the close future the next therapeutic goal is to 
eradicate the disease by implementing the use of TKIs (the actual golden standard in CML 
treatment), with drugs designed to target both cell-extrinsic and cell-intrinsic pathways 
sustaining LSCs life cycle (6, 9, 12). 
 
 
1.3 LSCs self-renewal and the Wnt/β-catenin/Tcf/Lef signaling pathway 
 
Many studies have been published that were focused on understanding the molecular 
mechanisms that allow CML stem cells to survive and that, once targeted, would enable 
their eradication or sensitization to TKIs and other antileukaemic drugs. Among these 
candidate pathways, those controlled by ALOX5, sonic hedgehog (SHH), STAT5, TGF-β 
and in particular Wnt were considered the most attractive (9, 12, 14). 
The Wnt family of secreted protein is composed of at least 19 isoforms of activating 
ligands for two distinct signaling pathways.  
Figure 5. Model of LSCs evolution 
  
The molecular evolution of hematopoietic stem cells (HSCs) into LSCs initiate with the BCR-ABL 
translocation occurring at the stem cell level, followed by the expansion of the myeloid progenitors. The 
acquisition of additional signal transduction abnormalities such as over-expression of Bcl-2 or β-
catenin and dependence from Wnt signaling allows enhanced survival and self-renewal capacity of the 
granulocyte macrophage progenitor (GMP) population. These cell-intrinsic alterations induce LSCs 
expansion and survival, only in presence of supportive microenvironments. 
Illustration by Crews L.A., Jamieson C.H.M. Cancer Letters, 2013; 338 15-22. 
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The “non-canonical” Wnt signaling pathway is characterized by a β-catenin independent 
mechanism that influence cell polarity, division and migration during development (8,15). 
On the other hand, the “canonical” Wnt signaling pathway controls the amount of the 
transcriptional co-activator β-catenin protein that drives specific gene expression 
programs. As such, several biological processes can be orchestrated, including cell fate 
determination, cell proliferation, stem cell maintenance, tumorigenesis and cancer 
progression (16). The key regulatory step of this pathway involves the phosphorylation, 
ubiquitination and subsequent degradation of β-catenin (16,21).  
Specifically, in the absence of Wnt (WNT-off state, Figure 6), β-catenin protein is 
constantly degraded in the cytoplasm by the action of Axin complex, composed of the 
scaffolding protein Axin, the tumor suppressor adenomatous polyposis coli (APC) gene 
product, the casein kinase 1 (CK1), and the glycogen synthase kinase 3 (GSK-3β). Axin 
coordinates sequential phosphorylation of β-catenin by CK1α, on serine 45, and by GSK-
3β, on threonine 41, serine 37 and serine 33. Phosphorylation of β-catenin on serine 33 
and 37 creates a binding site for β-Trcp (an E3-ubiquitin ligase), thus enabling 
ubiquitination and proteasomal degradation of β-catenin. Moreover, the regulator of G 
protein (RGS) domain within Axin allows interaction with β-catenin through APC (22,23,24). 
The continuous degradation of β-catenin through this cascade of events prevents its 
translocation in the nucleus and, consequently, interaction with members of the T cell 
factor/lymphoid enhancer factor (Tcf/Lef) family of proteins. Accordingly, Wnt-driven gene 
transcription is repressed by the binding of the transcriptional corepressor Groucho/TEL to 
Tcf/Lef proteins, and the recruitment of histone deacetylases (HDAC) (23). 
 
 
Figure 6. Overview of Wnt-off state 
 
In the absence of Wnt, the serine 
threonine kinases, CKI and GSK-3β 
phosphorylate β-catenin.  
β-catenin is recognized by β-Trcp, a 
component of E3 ubiquitine ligase 
complex.  
Following ubiquitination, β-catenin is 
targeted to a rapid destruction by the 
proteasome. 
In the nucleus, the transcription of 
Wnt target genes is inhibited by the 
corepressor protein Groucho/TLE 
(TLE) and histone deacetylases 
(HDAC). 
Illustration by Bryan T. MacDonald et 
al., Dev Cell. 2009 July; 17(1): 9-26. 
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Several reports revealed that in colon adenocarcinoma and other type of cancers, 
missense mutation or deletion of presumptive GSK-3β phosphorylation sites in the β-
catenin N terminus, make the protein resistant to regulation by the GSK-3β/APC/Axin 
complex (23,25,26). The consequences of these mutations are: an increase in β-catenin 
cytoplasmic and nuclear levels, constitutive interaction of β-catenin with Tcf/Lef 
transcription factors, and activation of Tcf/LEF driven genes (23,27,28). 
Contrariwise, on the Wnt-on state (Figure 7), Wnt ligand binds to a seven-pass 
transmembrane Frizzled (Fz) receptor and its co-receptor, low-density lipoprotein receptor 
related protein 6 (LRP6) or its close relative LRP5 (23,29). 
The formation of Wnt-Fz-LRP6 complex, together with the engagement of the scaffolding 
protein Dishevelled (Dvl), determines LRP6 activation by phosphorylation and the 
recruitment of Axin 1 to the receptor complex. These events lead to the inhibition of Axin-
mediated β-catenin phosphorylation by CK1 and GSK-3β, causing β-catenin protein 
stabilization. Therefore, β-catenin moves into the nucleus to form complexes with Tcf/Lef 
proteins that enable the expression of Wnt-targeted genes responsible for cell growth and 
impairment of the apoptotic program (e.g c-myc oncogene).  
From literature it is also known that nuclear accumulation of β-catenin impairs the 
transcription of the tumor suppressor gene CDKN2A, which encodes a protein (p16INK4a) 
endowed with an inhibitory function on cell cycle progression (23,30). 
 
 
 
 
 
Figure 7. Overview of Wnt-on state 
 
In the presence of Wnt ligand, the 
Fz/LRP5/6 co-receptor complex 
activates the canonical signaling 
pathways. 
Fz interacts with Dsh and induce the 
recruitment of Axin. 
The recruitment of Axin away from the 
“destruction” complex leads to the 
stabilization of β-catenin.  
In the nucleus, β-catenin interacts with 
Tcf/Lef to promote the transcription of 
Wnt targeted genes. 
Illustration by Bryan T. MacDonald et 
al., Dev Cell. 2009 July; 17(1): 9-26. 
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As regards CML, several studies indicated that deregulation of the Wnt/β-catenin axis 
occurs during the progression of the disease from chronic to accelerate and, finally, to 
blast crisis phases. It is well known, indeed, that normal hematopoietic stem cells (HSCs) 
self-renewal is sustained by β-catenin function but, on the pathological side, also CML 
progression towards the blast crisis seems to be consequent to the activation of β-catenin 
in GMP, in which it supports self-renewal and leukeamogenesis (14,17,18). Although Wnt is 
the physiological trigger of β-catenin, BCR-ABL is able to sustain this activation, even 
independently of Wnt, by means of phosphorylation of β-catenin on tyrosine residues (Y86 
and Y654) (Figure 8). Furthermore, as established in recent studies, BCR-ABL inhibits, by 
an Akt-dependent phosphorylation, the glycogen synthase kinase 3β (GSK-3β), a key 
regulator of β-catenin ubiquitination and proteasomal degradation (Figure 6)(19). The 
serine/threonine kinase GSK-3β is indeed pivotal in multiple cellular processes including 
nutrient and energy homeostasis, proliferation and apoptosis, cell fate specification and 
stem cell self-renewal. As such, GSK-3β plays an essential role also linking the canonical 
Wnt pathway with the PI3K/Akt axis (17,19,20). These findings suggest that β-catenin is likely 
to be an “hot-spot” for targeting LSCs self-renewal also in CML patients and therefore, to 
establish new treatments protocols in association with TKIs. However it should be noted 
that genetic deletion of β-catenin after CML initiation, does not lead to a complete 
remission of the disease, suggesting that other factors may sustain the progression of 
CML. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  Schematic representation of β-catenin activation induced by BCR-ABL 
 
X
β-catenin 
BCR-ABL 
PI3K AKT GSK-3β 
p Ser9 
p Tyr86 
p Tyr654 
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1.4 Mammalian target of Rapamycin (mTOR) signaling pathway 
 
Adding to its function in canonical Wnt/β-catenin signaling, previous works demonstrated 
that GSK-3β phosphorylates and activates the tuberous sclerosis 2 (TSC2) protein, which 
possesses a GTPase-activating function (20,31,32). Active TSC2, in turn, repress Rheb (Ras 
homolog enriched in brain), the small G-protein indispensable for the activation of 
mammalian target of rapamycin-complex 1 (mTORC1) (20,33,34). The Mammalian target of 
rapamycin (mTOR), contained in this protein complex, is an evolutionarily conserved 
serine/threonine kinase that regulates several cellular processes such as cell growth, cell 
cycle, cell survival and autophagy (Figure 9)(35,36). Adding to this, recent reports indicate 
that mTOR drives also stem cell proliferation and self-renewal, and, more specifically, in 
BCR-ABL transformed cells (20). 
More in general, mTOR takes can be recruited in two different protein complexes, 
mTORC1 and mTORC2 (Figure 9). mTORC1, comprises also proteins such as Raptor 
(regulatory associated protein of mTOR), mLST8 (GβL, mammalian lethal with sec13 
protein 8), PRAS40 (proline-rich Akt substrate of 40 kDa) and Deptor. This complex is 
directly regulated by cellular energy and nutrient levels, plays an essential role in the 
regulation of translation and is sensitive to inhibition by rapamycin. The small GTPase 
Rheb, the key upstream activator of mTORC1, is negatively regulated by TSC2. 
Physiologically, mTORC1 is activated by growth factors downstream of PI3K and Ras 
signaling pathways, through the direct phosphorylation and inactivation of TSC2 that relies 
on the activity of Akt and other kinases (extracellular signaling regulated kinase, ERK, p90 
ribosomal protein S6 kinase, RSK). However, when growth factor stimulation is withdrawn, 
TSC2-dependent inhibition of mTORC1 causes the cell to engage autophagy as an 
emergency response. Moreover, also a breakdown in energy supply negatively regulates 
mTORC1 formation consequently to the phosphorylation of Raptor by the AMP-activated 
protein kinase (AMPK).  
The signaling downstream of mTORC1 mainly implies the phosphorylation and activation 
of p70 ribosomal S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 
(4E-BP1), likely to be recruited by Raptor that acts as a scaffolding protein (Figure 
9)(34,35,36). mTORC1-dependent phosphorylation of S6K1 (on threonine 389), is required to 
recruit the phosphoinositide-dependent-kinase-1 (PDK1) and to stimulate mRNA 
processing, protein synthesis and cell growth. On the other hand, 4E-BP1, which is a 
member of the 4EBP family having a repressive function on translation initiation, 
dissociates from eIF4E upon mTORC1-dependent phosphorylation, thus enabling 
progression of protein synthesis. Recent studies also demonstrate that 4E-BP1 is a crucial 
element of the mTORC1 pathway affecting cell number and proliferation (36).  
The alternative complex, mTORC2, consists includes Rictor (rapamycin-insensitive 
companion of mTOR), mSin1 (mammalian stress-activated mitogen-activated protein 
kinase-interacting protein 1), PRR5 (proline-rich region 5), mLST8 and Deptor (Figure 9).  
This complex is not directly influenced by cellular energy and nutrient levels and it is 
insensitive to inhibition by rapamicyn. Biochemical and genetic evidence is provided that 
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mTORC2 phosphorylates Akt at serine 473, creating a mechanism of resistance to pro-
apoptotic stimuli (35,36) (Figure 9). 
 
 
 
 
 
 
 
Figure 9. Overview of mTOR signaling pathway 
 
mTOR is an evolutionarily conserved serine/threonine protein kinase that regulates several cellular 
processes such as cell growth, cell cycle, cell survival and autophagy; it is charactherized by two 
functional complexes mTORC1 and mTORC2. mTORC1 is directly regulated by cellular energy and 
nutrient status, plays an essential role in the regulation of translation and autophagy and is sensitive to 
inibhition by rapamycin. Instead, mTORC2 is not directly regulated by cellular energy and nutrient status, 
is insensitive to inhibition by rapamicyn and phosphorylates Akt at serine 473, therby contributing to 
growth factor-mediated Akt activation. 
Illustration by Cell Signaling Thecnologies Pathways web site (www.cellsignaling.com ). 
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1.5 AMPK signaling pathway 
 
As already stated, under metabolic stress conditions, mTORC1 activity is inhibited by 
AMPK. It has been shown that AMPK inhibits mTORC1 by two different mechanisms: one 
through the activation of TSC2, which promotes the inhibition of Rheb, and the other 
through direct phosphorylation of Raptor at serine 792 (Figure 11) (36,40). 
AMPK is a highly conserved serine/threonine protein kinase, found in all eukaryotes, 
member of the AMPK-related kinase family (36,37,38), which works as metabolic sensor to 
govern glucose and lipid metabolism in response to alteration in nutrients and intracellular 
energy levels. AMPK is a hetero-trimer comprising the catalytic α subunit and two other 
subunits, β and γ, with regulatory function. In mammals, each subunit has multiple 
subtypes; in particular, there are two isoforms of the catalytic subunit α (α1 and α2), while 
β and γ subunits have respectively two (β1 and β2) and three isoforms (γ1, γ2, γ3). The β 
subunit functions as a scaffold, that brings together α and γ subunits. The γ subunit 
contains four repeats of the cystathionine beta synthase (CBS) homology domains 
conferring the ability to bind molecules with adenosyl groups, i.e. AMP, ADP and ATP 
(Figure 10)(38).  
This kinase AMPK is activated by phosphorylation of the threonine 172 residue located in 
the activation loop of the α subunit, an event that is catalyzed by upstream kinases, such 
as liver kinase B1 (LKB1) and Ca2+/Calmodulin-dependent protein kinase kinase-β 
(CaMKK-β) (Figure 10). While CaMKK-β-dependent activation of AMPK is under control of 
intracellular Ca2+ currents (36,39), the tumor suppressor LKB1 activates AMPK in response 
to a decline of ATP levels as occurs upon nutrient starvation, ischemia and hypoxia. Under 
these conditions, active AMPK phosphorylates many substrates to turn on catabolic 
pathways, in order to generate more ATP, and to turn off those processes that are energy 
demandings (36,38).  
 
 
Figure 10. Structure and regulation of AMPK 
 
AMPK is a heterotrimeric protein consisting of three different 
subunits:  α, with catalytic function, and β and γ, which are 
regulatory of AMPK catalysis. AMP binding to the regulatory γ 
subunit of AMPK promotes the phosphorylation and activation 
of the α subunit (on threonine 172) by the upstream kinase 
LKB1. Alternatively, this kinase is activated by CaMKK-β in 
response to intracellular Ca2+ currents. 
Illustration by J Jeyabalan, et al., Journal of Endocrinology, 
2012; 212: 277–290. 
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Recently, several works demonstrated that pharmacological activators of AMPK, such as 
metformin and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), suppress the 
activation of mTORC1 pathway in BCR-ABL positive cells. Strikingly, treatments with these 
compounds induce a potent suppression of cell proliferation in Ph+ CML and acute 
lymphoblastic leukaemia (ALL) models, including cells expressing the T315I mutant of 
BCR-ABL (40,41). 
 
 
 
 
 
 
 
 
 
Figure 11. Regulation of mTORC1 by AMPK 
 
AMPK inhibits the pathway of mTORC1 in multiple mechanisms. Under energetic stress condition, 
AMPK phosphorylates TSC2 and Raptor to inhibit the mTORC1 complex. 
Illustration by Ken Inoki et.al., Annu. Rev. Pharmacol. Toxicol. 2012;52:381-400. 
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1.6 Autophagy 
 
Macroautophagy (hereafter named autophagy) is a degradation process that, under 
homeostatic conditions or in response to stress signals, consists in the lysosomal break 
down of intracellular material to enable cell adaptation to developmental and 
environmental signals (42,44). 
Autophagy is evolutionarily conserved and, in eukaryotes, progresses through delineate 
steps for the encapsulation of long-lived proteins and unbroken organelles into double 
membrane vesicles named autophagosomes. Finally, autophagosomes fuse with 
lysosomes to form autophagolysosomes, in which lysosomal hydrolases digest the vesicle 
for final destruction and recycling (42,43).  
In more details, the formation of autophagosomes is a three step-process characterized by 
nucleation, elongation, and completion of an isolation membrane, or phagophore. This 
process is strongly regulated by a limited number of highly conserved genes called 
autophagy regulators (ATGs) (Figure 12)(42,44,45).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 12. Schematic diagram of the steps of autophagy 
 
Autophagy begins with the formation of the phagophore or isolation membrane. The concerted action of 
the autophagy core machinery proteins at the phagophore assembly site is thought to lead to the 
expansion of the phagophore into an autophagosome. The autophagosome can engulf bulky cytosolic 
material, including entire organelles. When the outer membrane of the autophagosome fuses with an 
endosome or directly with a lysosome, it forms an autophagolysosome. Finally, the sequestered material 
is degraded inside the autophagolyosome and recycled. 
llustration by Zhiping Xie, Daniel J. Klionsky, Nature Cell Biology, 2007; 9:1102 –1109. 
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By allowing metabolic adaptation of the cell to multiple stresses, such as a decrease in 
nutrients, alterations of the oxidative metabolism, hypoxia, engulfment of endoplasmic 
reticulum and viral infections, autophagy provides an escape form apoptotic death 
(programmed cell death). However, depending on the duration and/or the intensity of the 
initial stress, autophagic cells may engage a specific cell death program called 
“autophagic cell death” (ACD) or type II cell death (44,46). 
Autophagy is found activated also in cancer cells in which it may promote cancerogenesis. 
On the other hand, evidence has been provided that autophagy can sometime increase 
apoptosis of cancer cells, thus expressing a tumor-suppressor function. Hence the precise 
role of autophagy during cancer progression is thought to be both tissue and context 
dependent (45,47). 
Another interesting aspect of autophagy is its involvement in the response to 
chemotherapy and radiation. Most of the studies indicate that autophagy inhibition 
sensitizes tumor cells to cell death induced by irradiation, alkylating agents or arsenic 
trioxide, suggesting that cancer cells can react to chemotherapy by inducing autophagy as 
a self-defense mechanism. Following anti-cancer treatments, the high levels of autophagy 
observed in tumor cells commonly represent an adaptive response that enables survival. 
In line with this assumption, several works demonstrated that autophagy inhibition 
synergizes with chemotherapies underlining the possibility that, the pharmacological 
inhibition of autophagy may represent an adjuvant therapy for cancer (44,45,47). 
For instance, synergism between pharmacological inhibitor of autophagy and common 
chemotherapies has been confirmed by treating several type of cancer (glioma, multiple 
myeloma, breast, colon and prostate cancer), including CML. In the latter case, it was 
demonstrated that resistance to TKIs might in part rely on massive engagement of 
autophagy, providing the rational for inhibiting this process in view of a therapeutic 
response. Indeed, recent works demonstrates that imatinib-dependent inhibition of BCR-
ABL may cause the activation of autophagy, which is consequent to alterations in 
intracellular Ca2+ concentrations and ER stress. Thus, combination of imatinib and 
chloroquine, an inhibitor of the final step of autophagy (digestion of cytosolic material in 
the autophagolysosome), significantly augments cell death of CML blasts, independently 
of the stage of the disease. In support, similar results were obtained abrogating the 
expression (by means of RNA-interference) of essential autophagy genes (atg5, atg7). 
More importantly, it has been proved that LSCs (identified as the CD34+/CD38- 
subpopulation of leukaemic blasts) are intrinsically resistant to imatinib by virtue of efficient 
engagement of autophagy, reinforcing the clinical implication of treatments that impair this 
process (6,44,47). In agreement, also vorinostat (an HDAC inhibitor) was found synergetic 
with chloroquine in killing imatinib-refractory CML cells (45,47), suggesting a more general 
impact of autophagy inhibition on cancer therapy. 
All these studies were used in support of the first clinical trial that propose the inhibition of 
autophagy in the treatment of CML patients, named CHOICES (“Chlroquine and Imatinib 
Combination to Eliminate Stem cells”), which is currently on phase II (6,47). 
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1.7 Celecoxib and 2,5-Dimethylcelecoxib 
 
Celecoxib is a sulfonamide non-steroidal anti-inflammatory drug (NSAID) and a selective 
cyclooxygenase-2 inhibitor (COXIB) used in the treatment of osteoarthritis and rheumatoid 
arthritis (Figure 13). Beyond its use as anti-inflammatory drug, celecoxib is known to exert 
an anti-proliferative control in many models of solid tumours. In particular, it is the only 
NSAID that has been approved for adjuvant treatment of patient with familial adenomatous 
polyposis. However, the antitumor activity of celecoxib in hematopoietic tumors, especially 
in CML, has not established so far (48,49). 
Celecoxib is able to inhibit both cyclooxygenases 1 (COX-1) and 2 (COX-2), although it is 
10-20 times more selective towards the latter isoenzyme. 
 
 
 
COXs are the key enzymes that catalyze the conversion of arachidonic acid to 
prostaglandins and other eicosanoids. In most tissues, COX-1 is expressed constitutively, 
whereas growth factors, cytokines and carcinogens may induce the expression of COX-2. 
Strikingly, high levels of PGE2 associated to an over-expression of COX-2 have been 
documented in several malignancies of colon, breast, prostate, pancreas and skin (50). 
Such over-expression of COX-2 in tumor cells is suggested to generate several cancer-
promoting effects, e.g. the over-expression of pro-angiogenic factors (VEGF, IL6, IL8), the 
activation of metalloproteases (MMP1, MMP2) and resistance to apoptosis inducing 
stimuli. The underlying mechanism proposed to explain some of the pro-survival effects of 
COX-2 hyperactivity is the increased conversion of arachidonic acid to PGE2 that, through 
the engagement of EP (1, 2, 3 and 4) class of g protein-coupled receptors (GPCR), causes 
cellular responses. For instance, acting on EP2 and 3 receptors of the cancer cell, PGE2 is 
entitled to sustain proliferation, consequent to impairment of the p27 CDK inhibitor, and, at 
the same time, to inhibit apoptosis through an up-regulation of Bcl-2 (51). Moreover, PGE2 
may exert its cancerogenic potential at the level of the immune system, where it co-
operates with macrophages to provide a “tumor supportive” microenvironment (50,52). 
Nevertheless, there are an increasing number of reports indicating that celecoxib does not 
require the presence of COX-2 in order to exert its antitumor activities. The hypothesis of 
COX-2-independent effects are based on the evidence that celecoxib exerts its anti-
proliferative and pro-apoptotic function also in cancer cell lines that do not express COX-2 
Figure 13. Chemical structure of celecoxib 
 
Illustration by Schönthal AH, British Journal 
of Cancer, 2007; 97, 1465-1468. 
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(53,54). In line with those findings, it was also demonstrated that 2,5-dimethylcelecoxib 
(DMC), a close structural analogue of celecoxib devoid of COX-2 activity, is able to 
potently mimic all antitumor proprieties of celecoxib (Figure 14)(55,56,57).  
 
 
 
 
 
 
To this regard, recent reports have proposed some molecular targets alternative to COX-2, 
such as: PDK1 (Phosphoinositide-Dependent Kinase-1), SERCA (Sarco/Endoplasmatic 
Reticulum Ca2+ATPase), carbonic anhydrase, and 5-lipoxygenase (ALOX5)(48,57,58). Finally, 
more recent studies on human colon carcinoma models have identified in β-catenin and its 
underlying pathway a possible target for COX-2-idependent action of celecoxib (59). 
Thus, in absence of a functional COX-2 enzyme, it is of great importance to evaluate the 
potential involvement non-COX-2 targets, already proposed or yet to be identified, in order 
to propose and optimize the use of celecoxib in the treatment of responsive cancers 
(55,60,61). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Chemical structure of 2,5-dimethylcelecoxibcelecoxib 
 
Illustration by Schönthal AH, British Journal of Cancer, 2007; 97, 1465-1468. 
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2. Materials and Methods 
 
 
2.1 Cell Cultures  
 
The BCR-ABL positive, human CML cell lines K562, LAMA-84 and JURL-MK1, which are 
provided by the American Type Culture Collection (ATCC, Rockville, MD, USA), have 
been established form the peripheral blood of three different patients during the blast crisis 
stage of the disease. Cell lines were grown in suspension in presence of Roswell Park 
Memorial Institute medium (RPMI-1640; Sigma-Aldrich Inc., Milan, Italy) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS, Immunological sciences, Rome, Italy), 
l-glutamine 50 mg/mL (Sigma-Aldrich Inc., Milan, Italy), penicillin 10 U/mL and 
streptomycin 100 mg/mL (Sigma-Aldrich Inc., Milan, Italy).  
The cell line expressing the β-catenin S33Y mutant was obtained by gene transfection 
(see further in the text) and it was maintained in a RPMI-1640-based medium, as 
described for the parental cell line LAMA-84. 
AMPKα-silenced cells, AMPKα-, and their un-targeted counterpart, SCR, were obtained by 
lentiviral delivery of microRNAs (see further in the text), and were cultured as the originator 
cell line, LAMA-84. 
HeLa cells were obtained from ATCC (Rockville, MD, USA) and were cultured in Modified 
Eagle’s Medium (MEM; Sigma-Aldrich Inc., Milan, Italy), supplemented with 10% heat-
inactivated FBS (Immunological sciences, Rome, Italy), l-glutamine 50 mg/mL (Sigma-
Aldrich Inc., Milan, Italy), penicillin 10 U/mL and streptomycin 100 mg/mL (Sigma-Aldrich 
Inc., Milan, Italy). 
All cell lines were kept in culture at 37 °C, under a 5% CO2 humidified atmosphere.  
 
 
2.2 Chemicals 
 
Celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, 
200 mM stock solution;  Chemos GmbH, Regenstauf, Germany); rofecoxib (3-(4-
methylsulfonylphenyl)-4-phenyl-2H-furan-5-one, 50 mM stock solution; MSD Inc., Milan, 
Italy); MG132 (Z-Leu-Leu-Leu, 50 mM stock solution), BIO (10 mM stock solution), STO-
609 (10 mg/mL stock solution), all purchased from Sigma-Aldrich Inc., Milan, Italy; PP242 
(50 mM stock solution; Selleck Chemicals, Munich, Germany); imatinib (4-[(4-
methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-
2yl)amino]phenyl]benzamide; 50 mM stock solution; LKT Laboratories Inc., St. Paul, MN, 
USA); these compounds  were dissolved in 100% dimethyl sulfoxide (DMSO) and stored 
at +4 or -20°C, according to manufacturers’ specifications. Working concentrations of 
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these compounds were freshly prepared for each experiment by diluting DMSO to 0.1% in 
milliQ (MilliPore) water. 
A 100 mM stock solution of chloroquine (Sigma-Aldrich Inc., Milan, Italy) was obtained by 
diluting it in milliQ water (MilliPore) and stored at -20°C. 
2,5-dimethyl-celecoxib (4-[5-(2,5-dimethylphenyl)-3-(tryfluoromethyl)-1H-pyrazol-1-
yl]benzenesulfonamide, 100 mM stock solution; WITEGA Laboratorien GmbH, Berlin, 
Germany) was synthesized as follows by Dott. Minassi (Department of Pharmaceutical 
Sciences, Novara, Italy). 
 
 
2.3 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide  
      (MTT) assay 
 
Cells were plated in 96-well plates (100 µL/well) and treated at a 5-10x104cells/mL density. 
At the end of the treatments, the MTT reagent was added to cells at a final concentration 
of 0,25 mg/mL (Sigma-Aldrich Inc., Milan, Italy), for 90 minutes at 37°C. Reactions were 
then stopped and the crystal were solubilized by adding isopropyl alcohol/HCl (1:1; vol:vol) 
(Sigma-Aldrich Inc., Milan, Italy) plus 10% Triton X-100 (Sigma-Aldrich Inc., Milan, Italy), 
before reading the absorbance at 570 nm, using the multi-plate reader Victor3 V 
(PerkinElmer, Milan, Italy). 
 
 
2.4 Analysis of Cell Cycle distribution by Flow Cytometry 
 
At the end of the various treatments, 1x106 cells were collected, washed once with 
Phosphate Buffer Saline (PBS) and resuspended in a 70% ethanol solution. Following to 
overnight incubation at -20°C, cells were washed again with PBS and incubated with 
RNAase (100 µg/mL, Sigma-Aldrich Inc., Milan, Italy). Cells were then incubated in PBS 
containing 5 mM EDTA and 50 µg/mL propidium iodide (Sigma-Aldrich Inc., Milan, Italy) 
for 30 minutes, prior to flow cytometric analysis with Accuri-C6 flow cytometer (BD 
Bioscience, Milan, Italy). ModFit LT software was used for discrimination of different sub-
populations along the cell-cycle. 
 
 
2.5 Staining of apoptotic nuclei 
 
Nuclear DNA integrity was assessed through microscopy of cells stained with the DNA-
binding, supravital dye, Hoechst-33342 (Sigma-Aldrich Inc., Milan, Italy).  
Briefly, cell were incubated with 0.8 µg/mL Hoechst-33342 for 15 minutes at room 
temperature prior to fixation with 4% PBS/paraformaldehyde (Sigma-Aldrich Inc., Milan, 
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Italy), for 10 min at room temperature. Cells were then washed twice with PBS, spotted on 
a microscope slide by cyto-spinning (10 minutes x 1200 rpm) (Thermo Fisher Scientific 
Inc., Milan, Italy) and layered with mounting solution (DakoCytomation Carpinteria, CA, 
USA) and cover slip. Images (60x magnification, Nikon Instruments, Florence, Italy) were 
obtained through UV-excitation of the samples and documented with a digital camera 
(Nikon Instruments, Florence, Italy). 
 
 
2.6 Clonogenic Assay  
 
Cells were treated, for 24 hours at the 1x105cells/mL density, with the concentrations 
indicated for each drug (celecoxib, dimethyl-celecoxib, rofecoxib, PP242, STO-609, 
chloroquine and imatinib), or with vehicle (0.1% DMSO). Next, 1250 cells/well (in 6-well 
plates) were seeded into a semisolid culture media composed of 80% methylcellulose 
(MethoCult®, STEMCELL Tech., Milan, Italy) and 20% RPMI-1640 (fully supplemented). 
After 6 days, cell colonies were counted using a phase-contrast microscope.  
 
 
2.7 Immunoblottings 
 
Whole-cell extracts were obtained using the RIPA lysis buffer (50 mM Tris-HCl pH 7.4; 150 
mM NaCl, 0.5 mM EDTA pH 8, 1% Igepal, 0.1% SDS), supplemented with 1 mM 
phenylmethylsulphonyl fluoride, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 10 
mM glycerophosphate, 0.5 mM dithiothreitol and standard protease inhibitor cocktail 
(Roche Applied Science, Indianapolis, IN, USA).  
Lysates were clarified by centrifugation at 14000g for 15 minutes at 4°C. Protein 
concentrations were evaluated with Bradford reagent (Sigma-Aldrich Inc., Milan, Italy).  
For LC3 protein detection, cell extracts were obtained directly in 2xLaemmli sample buffer, 
supplemented with β-mercaptoethanol (Sigma-Aldrich Inc., Milan, Italy).  
Proteins were loaded onto SDS-PAGE gels for electrophoresis, and transferred onto 0.22µ 
nitrocellulose or PVDF membranes for immunodetection.  
The following primary antibodies were used: anti β-actin (clone AC-15 Sigma-Aldrich Inc., 
Milan, Italy); anti-COX-1 (clone H-62, Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA); anti-COX-2 (clone C-20, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); 
anti-β-catenin (clone 14, BD Bioscience, Milan, Italy); anti-non-phospho(active)-β-catenin 
(ser33/37/thr41, Cell Signaling Technology Inc., Danvers, MA, USA); anti-phospho-
AMPKα (thr172 clone 40H9) and AMPK-α (Cell Signaling Technology Inc., Danvers, MA, 
USA); anti-phospho-GSK-3β (ser9) and anti-GSK-3β (Cell Signaling Technology Inc., 
Danvers, MA, USA); anti-phospho-mTOR (Ser2448), anti-phospho-mTOR (ser2481) and 
mTOR (clone 7C10) (Cell Signaling Technology Inc., Danvers, MA, USA); anti-phospho-
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p70 S6 Kinase (thr389) and anti-p70 S6 Kinase (Cell Signaling Technology Inc., Danvers, 
MA, USA); anti-phospho-4E-BP1 (thr37/46) and anti-4E-BP1 (Cell Signaling Technology 
Inc., Danvers, MA, USA); anti-LC3B (Sigma-Aldrich Inc., Milan, Italy). 
Antibodies were all prepared in TRIS-buffered saline solution containing with 0.1% Tween-
20 (T-TBS), and supplemented with 3-5% non-fat dried milk or 3-5% bovine serum 
albumin, depending on the indications of the manufacturers.  
After over-night incubation at 4°C, membranes were washed trice in T-TBS and incubated 
(45 minutes at room temperature) with appropriate horseradish peroxidase-conjugate 
secondary antibody (Bio-Rad Inc., Milan, Italy), before visualization of the 
chemiluminescent substrate PDS-OVERTIME (Genespin, Milan, Italy). Images of the 
immunoreactive bands were acquired and analyzed using the ChemiDoc XRS device (Bio-
Rad Inc., Milan, Italy) and the Quantity-One software (Bio-Rad Inc., Milan, Italy). 
 
 
2.8 RNA extraction, reverse transcription and quantitative Real-Time 
PCR (qRT-PCR) 
 
Total RNA was extracted approximately from 5 x106 cells using TRI-Reagent® (Sigma 
Aldrich Inc., Milan, Italy). Im-Prom-II™ Reverse Transcriptase (Im-Prom-II™ Reverse 
Transcription System, Promega, WI, USA) was used to generate cDNA using 1 µg of RNA 
and oligo dT primers, according to the instructions of the manufacturer. Reverse 
transcription was performed using a thermal-cycler (Eppendorf, Germany) and the 
following heating protocol: 10 minutes at 25°C, 45 minutes at 42°C and 5 minutes at 99°C. 
cDNA was then stored at -20°C until further used. 
After setting gradient PCRs to verify primers specificity and melting temperature, standard 
curves of SYBR Green fluorescence were generated for each gene tested in order to 
evaluate primer efficiency.  
qRT-PCRs were performed on a 96-well plate, in triplicate, and florescence intensity 
assessed using the CFX96™ Real-Time PCR Detection Systems (Bio-Rad Inc., Milan, 
Italy). The following conditions were adopted: 12.5 µL Maxima™ SYBR Green/ROX qPCR 
Master Mix (Thermo Fisher Scientific Inc., Milan, Italy), 0,1 µM of forward and reverse 
primers, and 5 µL of 1:5 diluted cDNA, in a total volume of 25 µL/reaction.  
After an initial denaturation step at 95°C (10 minutes), each primer set was used (through 
40 cycles of amplification) as follows: human CTNNB1, 5’-ACCAGCGCCGTACGTCCAT-
3’ forward and 3’-GCTAGGATGTGAAGGGCTCCG-5’ reverse (104-bp amplicon) (Sigma-
Aldrich Inc., Milan, Italy), 60°C annealing temperature; human c-myc, 5’-
CAAAGACAGCGGCAGCCC-3’ forward and 3’-GCGAGGCGCAGGACTTG-5’ reverse 
(164-bp amplicon) (Sigma-Aldrich Inc., Milan, Italy), 64.4°C annealing temperature; human 
CDKN2A, 5’-CAACCTGGGGCGACTTCAG-3’ forward and 3’-GACCAGCCAGCCCCTCC-
5’ reverse (201-bp amplicon) (Sigma-Aldrich Inc., Milan, Italy), 61.7°C annealing 
temperature.  
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CTNNB1, c-myc and CDKN2A transcripts were normalized to the expression of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNAs, assessed using the 5’-
CAAGGTCATCCATGACAACTTTG-3’ forward and the 3’-GGGCAATCCACAGTCTTCTG-
5’ reverse primer (90-bp amplicon) (Sigma-Aldrich Inc., Milan, Italy), 60°C annealing 
temperature.  
At the end of the amplification cycles, amplicon/primers melting curves were generated 
measuring the SYBR Green fluorescence upon temperature ramping from 60°C to 95°C 
(0.3°C/s). For each gene, the threshold cycle (Ct) was calculated using CFX Manager 
Software (Bio-Rad Inc., Milan, Italy) by determining the cycle number at which the change 
in the fluorescence of the reporter dye crossed the threshold. The Ct of treated cells was 
compared to the Ct generated by the control cells and ΔCt was calculated as the difference 
between Ct values, determined using the equation 2-ΔCt. 
 
 
2.9 Constructs, transfection, lentiviral infection  
 
LAMA-84 β-catenin S33Y cells were obtained by stable transfection of a pcDNA3 plasmid 
carrying the cDNA for a Flag-tagged degradation-resistant mutant of β-catenin in which 
serine 33 has been replaced by a tyrosine (Addgene, Cambridge, MA, USA). 
Transfection was performed by using the X-tremeGENE reagent (Roche, Milan, Italy), 
according to the indications of the manufacturer. After 24 hours from transfection, cells 
were exposed for 10 days to the selecting agent G418 (0,8 mg/mL; Sigma Aldrich Inc., 
Milan, Italy). The expression of the exogenous protein (S33Y β-catenin) was verified by 
immunoblots with the anti-Flag rabbit polyclonal antibody (Sigma Aldrich Inc., Milan, Italy). 
To knock-down of the AMPKα kinase, pGIPZ vectors carrying the non-targeting (SCR) or 
nine different AMPKα-specific (AMPKα-) miRNAs (all obtained through access to the Open 
Biosystems library, at the Cancer Institute, University College of London) were screened in 
preliminary experiment by using the immunoblotting technique.  
Lentiviral supernatants were prepared, following to the manufacturer’s instructions, using 
the HEK-293T cell lines for virus packaging. Cell were transfected with a mix (4:3:1) of 
pGIPZ (carrying miRNA sequence and the reporter gene turbo-Green Fluorescence 
Protein, tGFP), psPAX2 (carrying the HIV-derived gag/pol, rev and tat sequences) and 
pMD2.G plasmids (coding for the env protein of the Vesicular Stomatitis Virus G, required 
for virion pseudotyping) using the METAFECTENE® PRO reagent (Biontex Laboratories 
GmbH, Germany). 
Lentiviral particles were concentrated after two centrifugation steps (1.500 g, 4°C) in a 
solution containing polyethylene glycol (PEG MW8,000, Sigma Aldrich Inc., Milan, Italy) 
and then re-suspended in PBS (1/50 of the initial volume).  
Titration was performed on HeLa cells infected with (1:5) serial dilutions of the viral 
suspension. Infection efficiency was calculated by assessing, through flow cytometry, 
percentages of cells expressing the tGFP reporter gene contained in the pGIPZ plasmid. 
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The infections were carried out by spinoculation procedure. Briefly, 1x106 cells/mL, plated 
in 6-well plates, were exposed to viruses at a concentration of 10 multiplicity of infection 
(MOI) in presence of 8µg/mL of Polybrene® (Sigma Aldrich Inc., Milan, Italy). Incubation 
with viruses was allowed upon centrifugation for 45 minutes at 1260rpm; next, cells were 
incubated for 5 hours at 37°C before being switched to regular medium.  
Green fluorescence intensity was used as reference parameter in order sort out (using the 
FACS-Vantage cell sorter) the population of cells with the highest levels of viral integration.  
Finally, the down-regulation of AMPKα was verified by probing protein lysates with the 
anti-AMPKα rabbit polyclonal antibody (Cell Signaling Technology Inc., Danvers, MA, 
USA). 
 
 
2.10 Immunofluorescence and Autophagy assessment 
 
Following treatments with drugs (celecoxib and chloroquine), cells were fixed with 4% 
PBS/paraformaldehyde (Sigma Aldrich Inc., Milan, Italy) for 15 minutes at room 
temperature. Next, cell were washed three times with PBS and then permeabilized using 
0,1% Triton X-100/PBS (Sigma-Aldrich Inc., Milan, Italy) for 10 minutes. After three 
washing steps, saturation of unspecific epitopes was achieved through incubation with the 
PBG buffer (0.5% bovine serum albumin, 0.2% gelatin from cold water fish skin in PBS; 
Sigma-Aldrich Inc., Milan, Italy) for 60 minutes at room temperature, before adding the 
rabbit anti-LC3B antibody (Sigma-Aldrich Inc., Milan, Italy), which was incubated for 90 
minutes at room temperature. Finally, LC3-postive structures were visualized, after three 
washes with PBS, by incubation (for 30 minutes at room temperature) with an anti-rabbit 
secondary antibody conjugated with the fluorochrome Alexa-Fluor488 (Life Technologies 
Corporation, Milan, Italy). Nuclei were counter stained using Hoechst-33342 (Sigma-
Aldrich Inc., Milan, Italy). Cells were then spotted on a microscope slide by cyto-spinning 
(10 minutes x 1200 rpm) (Thermo Fisher Scientific Inc., Milan, Italy) and layered with 
mounting solution (DakoCytomation Carpinteria, CA, USA) and cover slip. Images (60x or 
100x magnifications) were acquired using an inverted microscope equipped with epi-
fluorescence attachment and a digital camera (Nikon Instruments, Florence, Italy). 
A minimum of 200 cells was counted for each treatment and replicated in three 
independent experiments. Autophagic cells were identified as those displaying at least four 
LC3-positive puncta. 
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2.11 Statistical Analysis 
 
The results in this study are presented as mean (± standard error) of the results obtained 
from three independent experiments. Statistical analyses were performed using Student’s 
t-test. Statistical significance was indicated as follows: P<0.05 (*), P<0.01 (**), P<0.001 
(***). 
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3. Results 
 
3.1 Celecoxib impairs proliferation of CML cell lines 
 
To investigate the effects of celecoxib on CML viability we generated concentration-
response curves in three p210-BCR-ABL-expressing CML cell lines (K562, LAMA-84, 
JURL-MK1), exposed to this drug for 24 hours using the MTT assay (Figure 15a). 
Proliferation inhibition, reflected by the ability of celecoxib to suppress cellular metabolism 
of the tetrazolium substrate used for this assay, was especially evident in the LAMA-84 cell 
line (EC50 of about 23,8 µM), while the JURL-MK1 was the most resistant of the three 
lines (EC50 of 75,2 µM). The impact of celecoxib on tetrazolium conversion was also 
irreversible and time-dependent since the EC50, calculated 6 days after a single 
administration of this drug, was consistently lower than at 24 hours (8,2 µM for LAMA-84 
and 23,8 µM for JURL-MK1) (Figure 15b). 
A careful analysis of the data also revealed that, after 24 hours, MTT absorbance of 
celecoxib-treated cells, although reduced in comparison to control groups (0,1 % DMSO, 
used as vehicle), did not reach levels below the time-zero point (unless using 
concentrations higher than 25 µM, Figure 15a), implying a cytostatic rather than a 
cytotoxic effect. Cell counting with a hemocytometer confirmed that numbers lower than 
those of time-zero were observed in the celecoxib-treated group only at concentrations 
higher than 25 µM (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Cell viability, dose-response curves of LAMA-84, JURL-MK1 and K562 cell lines 
evaluated by MTT assay. 
  
Cells were treated for: a) 24 hours with 6.25, 12.5, 25, 50, 100 µM celecoxib; b) or 6 days with 1, 2.5, 5, 
10, 25 µM celecoxib. Data represents averages of three independent experiments (± standard error).  
 
-150 
-125 
-100 
-75 
-50 
-25 
0 
25 
50 
75 
100 
125 
150 
0,1 1 10 100 
A
bs
 [5
70
 n
m
-b
] %
 o
f c
on
tr
ol
 
celecoxib [µM]  
MTT assay (24h) 
LAMA-84 
JURL-MK1 
K562 
0 
25 
50 
75 
100 
125 
0,1 1 10 100 
A
bs
 [5
70
nm
-b
]%
 o
f c
on
tr
ol
 
celecoxib [µM]  
MTT assay (6 days) 
LAMA-84 
JURL-MK1 
K562 
a) b) 
Chapter 3 	  	  
	   29	  
LAMA-84 cell cycle profiling, by means of flow cytometry of propidium iodide stained cells, 
evidenced that celecoxib, at concentrations close to the EC50 (25 µM), caused an 
increase in the apoptotic SubG1 peak (13,6 % vs 1,1% of controls) as well as in the G1 
cell subset (61,8 % vs 55,2 % of controls); these variations were associated to a 
contemporary depletion of the S (20,6 % vs 28,6) and G2 (4 % vs 15,1%) subpopulations. 
Conversely, celecoxib had no effect on the cell cycle distribution of JURL-MK1 cells 
(Figure 16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Cell-cycle distribution assessed by flow cytometry of LAMA-84 and JURL-MK1 cell lines.  
 
LAMA-84 (panel a) and JURL-MK1 cells (panel b) were treated for 24 hours with 25 µM celecoxib (cele) 
and stained with propidium iodide. Histograms display percentages of cell populations in the different 
phases of the cell cycle. Values are the averages of three independent experiments (± standard error). 
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Data generated by flow cytometry were further supported by trypan blue exclusion tests 
(Figure 17) and microscopic counting of fragmented nuclei stained with the Hoechst-33258 
florescent dye (Figure 18), which revealed that 25 µM celecoxib causes cell death only in 
the LAMA-84 cell line. 	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Figure 17. Trypan-blue exclusion test on LAMA-84 and JURL-MK1 cell lines. 
 
Cells were treated with 0.1% DMSO (ctrl) or 25 µM celecoxib (cele) for 24 hours. Histograms represent 
the percentages of, trypan blue-positive, dead cells. A minimum of 100 cells was scored in each condition. 
Values represent the means of three independent experiments (± standard error). *P ≤ 0,05, **P ≤ 0,01, 
***P ≤ 0,001 (student t-test). 
 
 
Figure 18. UV-fluorescent microscopy (600 X) of Hoechst33258-stained LAMA-84 and JURL-MK1 
cell nuclei. 
 
Cell lines were treated for 16 hours with 0.1% DMSO (ctrl) or 25 µM celecoxib (cele). Histograms 
represent the percentages of apoptotic cells presenting fragmented nuclei. Data express averages of three 
independent experiments (± standard error).  	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3.2 The effects of celecoxib are COX-2-independent 
 
To investigate whether the anti-leukaemia effects of celecoxib are due to inhibition of one 
or both cyclooxygenase isoenzymes, COX-1 and COX-2, we analyzed the expression of 
these proteins in K562, LAMA-84 and JURL-MK1 cell lines. Immunoblots of protein lysates 
revealed that the three cell lines express only moderate levels of COX-1, whereas 
expression of the COX-2 isoenzyme was not detected (NIH-3T3 and MSTO-211H protein 
lysates were used as positive controls respectively for COX-1 and COX-2 proteins; Figure 
19).  
 
  
 
 
 
 
 
 
 
 
To further confirm that the effects of celecoxib are COX2-independent, LAMA-84 and 
JURL-MK1 cell lines (for 24, 48 and 72 hours) were incubated with increasing 
concentrations of rofecoxib, another selective COX-2 inhibitor, and the 2,5-dimethyl 
derivative of celecoxib (DMC), which lacks COX-2-inhibitory function (55,56,62). The effects of 
these drugs on the viability of CML cell lines was evaluated by the MTT assay. Treatment 
with DMC mimicked the anti-leukaemia effects of celecoxib, of which it is more potent (at 
least in the JURL-MK1 cells; Figure 20). By contrast, rofecoxib had no effect, regardless of 
the concentration used or the cell line in which it was tested (Figure 21). 
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Figure 20. Cell viability evaluated by the MTT assay.  
 
LAMA-84 and JURL-MK1 cell lines were treated with increasing concentrations (12.5, 25, 50, 100 µM) of 
dimethyl-celelcoxib for 24, 48 and 72 hours. Values represent the mean of three independent experiments 
(± standard error). 
 
Figure 19. Protein levels of cyclooxygenase 1 (COX-1) 
and 2 (COX-2) in CML cell lines.  
 
Immunoblots were performed combining a monoclonal 
anti-COX-1 primary antibody with an HRP-conjugated 
secondary antibody produced in mouse, or a polyclonal 
anti-COX-2 primary antibody with an HRP-conjugated 
secondary antibody produced in goat. β-actin levels were 
used to assess the equivalence of protein loadings.  
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The therapeutic potential of putative anti-leukaemia drugs is also measured by their ability 
to suppress methylcellulose colony formation. Thus, LAMA-84 or JURL-MK1 cells were 
treated with increasing concentrations of celecoxib (or with vehicle, i.e. 0,1% DMSO), 
before plating equal numbers of cells (1,250 cells/well) into culture media containing 80% 
methylcellulose. Colonies were counted 6 days later and treatment with celecoxib 
suppressed colony formation in a concentration-dependent manner. While LAMA-84 cells 
were more sensitive than JURL-MK1 to treatment with celexoxib also in the clonogenic 
assays, the EC50 values for the methylcellulose assays (0,5 and 3,8 µM, respectively) 
(Figure 22) were markedly lower than for the MTT assays. In agreement to what was 
shown by the MTT assays, these effects did not rely on the inhibition of COX-2 since 
rofecoxib did not abolish or reduce, the formation of colonies in CML cell cultures, even at 
the 25 µM concentration (Figure 22).  	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Figure 21. Cell viability, dose-response curves of LAMA-84 and JURL-MK1 evaluated by the MTT 
assay.  
 
Cells were treated with increasing concentrations (6.25, 12.5, 25, 50 µM) of rofecoxib for 24, 48 and 72 
hours. Data express the averages of three independent experiments (± standard error).  
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Figure 22. Clonogenic assay, 
dose-response curves of 
K562, LAMA-84 and JURL-MK1 
cell lines (1250 cells/well) 
grown on 80% methylcellulose 
culture media.  
 
CML cell lines were treated with 
celecoxib (0.1, 0.25, 0.5, 1, 2.5, 
5, 10, 25 µM) or rofecoxib (rofe; 
25 µM) for 6 days. Results are 
expressed as percentages of 
colonies counted in drug-treated 
groups as compared to 0.1% 
DMSO-treated controls. Values 
represent the mean of three 
independent experiments made 
in duplicate (± standard error). 
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3.3 The β-Catenin/Tcf/Lef axis is impaired by celecoxib 
  
A great deal of attention has recently been paid to the role of signal transduction pathways 
that maintains the self-renewal of leukemic blasts. Like other types of leukaemias, CML 
stem-cells appear to rely on these pathways and in particular on the activation of the β-
catenin/Tcf-Lef-dependent transcription program activated in normal cells by Wnt (63). 
Indeed, it is becoming clear that this pathway is aberrantly activated in CML blasts both in 
the chronic phase and the blast crisis stage of the disease (24). More intriguingly, recent 
studies have shown that BCR-ABL may sustain the activation of β-catenin independently 
of Wnt; in particular BCR-ABL can inhibit the glycogen synthase kinase 3β (GSK-3β) that 
regulates ubiquitination and proteasomal degradation of β-catenin, and activate the 
transcriptional function of β-catenin by direct phosphorylation on tyrosine residues (17,45). 
Thus, we assessed the effects of celecoxib on β-catenin protein levels in drug-treated (25 
µM; 2-24 hours) LAMA-84 and JURL-MK1 cells. Immunoblots of protein lysates probed 
with an antibody specific for β-catenin revealed that, in LAMA-84 cells, celecoxib treatment 
caused a marked decrease of β-catenin levels that was already visible after 2 hours, and 
reached a peak after 8-16 hours. By contrast, in JURL-MK1 cells, celecoxib had no effect 
on β-catenin protein levels at any time-point (Figure 23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Since the down-regulation of a given protein may be due to decreased expression or 
enhanced degradation, we assessed first, the effect of 25 µM celecoxib on β-catenin 
mRNA levels using the real-time PCR approach. As shown in Figure 24, already after 2 
hours of treatment, celecoxib strongly reduced (almost by 80%) the expression of β-
catenin mRNA in LAMA-84 cells. This effect, which lasted at least for 24 hours after a 
single administration of celecoxib, was not observed in the drug-resistant JURL-MK1 cell 
model (Figure 24).  
JURL-MK1    
β-actin 
β-catenin 92kDa  
43kDa  
β-catenin/β-actin       1      0,94    1,28    1,72    1,07     1        
LAMA-84    
ctrl 2h 4h 8h 16h 24h 
β-catenin 
β-actin 
92kDa  
43kDa  
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celecoxib Figure 23. Protein levels of β-
catenin in LAMA-84 and JURL-
MK1 cell lines exposed to 25 µM 
celecoxib. 
 
Cells were treated for 2, 4, 8, 16 and 
24 hours before isolating protein 
lysates. Immunoblots were 
performed using a monoclonal anti-
β-catenin primary antibody and a 
HRP-conjugated secondary antibody 
produced in mouse. Odds represent 
the “relative intensity” of β-catenin 
immuno-reactive bands corrected by 
the levels of β-actin, used to 
normalize protein loadings 
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On the other hand, since β-catenin protein stability is largely dependent on proteasomal 
degradation, we evaluated if the pharmacological inhibition of this process rescued the 
expression of the protein in the presence of 25 µM celecoxib. Indeed, levels of β-catenin 
protein detected in LAMA-84 cells treated with the proteasome inhibitor MG132 (20 µM), 
given alone, or in combination with 25 µM celecoxib (Comb.) were higher not only of those 
in cells treated only with celecoxib, but also of those of the 0.1 % DMSO-treated controls 
(Figure 25).  
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     JURL-MK1 1,356±0,280 1,116±0,170 1,343±0,230 
Figure 24. Transcriptional levels of the β-catenin gene (CTNNB1) in LAMA-84 and in JURL-MK1 cell 
lines treated for 2, 8 and 24 hours with celecoxib (25 µM).  
 
Histograms represent the ratio between CTNNB1 mRNA levels in celecoxib-treated or 0.1% DMSO-
treated (ctrl) groups, which were measured by means of the real-time PCR technique. The levels of 
CTNNB1 mRNAs were normalized using the expression of GAPDH as housekeeping gene. Values 
represent means of three independent experiments (± standard error). *P ≤ 0,05, **P ≤ 0,01, ***P ≤ 0,001 
(student t-test).  
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Figure 25. MG132 (a proteasome-specific 
inhibitor) reverts the effects of celecoxib on 
β-catenin protein degradation.  
 
LAMA-84 cells were treated for 2 hours with 
celecoxib (25 µM) or MG132 (20 µM), alone or in 
combination (Comb.). Immunoblots were 
performed using a monoclonal anti-β-catenin 
primary antibody as described in Figure 23. The 
levels of β-actin are displayed as proof of 
equivalent loadings. 
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Since a precondition to proteasomal degradation of β-catenin is its GSK-3β-dependent 
phosphorylation on amino-terminal serine residues, we monitored the activity of this kinase 
following to treatment with 25 µM celecoxib. Thus, we measured the levels of the inactive 
form of GSK-3β generated via Akt-dependent phosphorylation of its serine-9 (ser-9) 
residue (64). 
As shown in Figure 26, by comparing immunoblots of phospho-ser9 and total GSK3-β 
protein levels, it was evident that celecoxib, already after a 4-hours treatment, was able to 
inhibit ser-9 phosphorylation, restoring the activity of this kinase. By contrast, celecoxib did 
not affect the phosphorylation of GSK-3β in the more resistant JURL-MK1 cells (Figure 
26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The role of GSK3-β re-activation in the celecoxib-induced degradation of β-catenin was 
clearly demonstrated by using this drug in presence of an inhibitor of this kinase. Indeed, 
LAMA-84 cells treated for 4 hours with the GSK3-β inhibitor, BIO (10 µM), given alone or 
in combination with 25 µM celecoxib (Comb.) displayed levels of β-catenin higher than 
those detected in celecoxib- or in 0.1 % DMSO-treated controls (Figure 27). 
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After 2, 4 and 8 hours in 
presence of 25 µM celecoxib, 
LAMA-84 and JURL-MK1 protein 
lysates were probed with a 
primary antibody specific for the 
phospho-serine 9 epitope of 
GSK-3β (p-GSK-3β  Ser9) and 
detected by using a HRP-
conjugated secondary antibody 
produced in rabbit. Levels of total 
GSK-3β protein were assessed to 
equalize protein loadings. 
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Figure 27. Celecoxib restores GSK-3β  
activity.  
 
LAMA-84 cells were treated for 4 hours 
alternatively with: 25 µM celecoxib, 10 µM 
BIO, or a combination of both (Comb.). 
Protein lysate were probed with an anti-β-
catenin mouse monoclonal antibody and 
HRP-conjugated secondary antibodies 
produced in mouse. β-actin levels are 
displayed as proof of equal loadings. 
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Previous studies showed that cytosolic stabilization of unphopshorylated β-catenin allows 
the translocation into the nucleus to form complexes with transcriptional factors of the Tcf 
(T-cell factor)/Lef (lymphoid enhancing factor) family (23,28). Thus, by immnublotting protein 
lysates of LAMA-84 cells with an antibody recognizing only the unphosphorylated form of 
β-catenin (actβ-cat), we observed that celecoxib was able to reduce the levels of the 
transcription-competent form of this protein in a time- (Figure 28a) and concentration-
dependent manner (Figure 28b). These effects were also evident after correcting the 
levels of active β-catenin by the total levels of this protein (Figure 28b). On the other hand, 
celecoxib was not able to affect the levels of active- β-catenin when testing the drug-
resistant cell line JURL-MK1  (Figure 28a). 
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Figure 28. Celecoxib reduces the levels of the transcriptional-active form of β-catenin (act-β-cat) in 
a time and concentration dependent manner.  
 
a) LAMA-84 and JURL-MK1 cell lines were treated for 4, 8, 16 and 24 hours with 25 µM celecoxib. 
Immunoblots on protein lysates were performed using a polyclonal antibody that recognize β-catenin only 
when unphosphorylated at the Ser33/37/Thr41 epitopes (the transcriptional-active form; act-β-cat). A 
HRP-conjugated secondary antibody produced in rabbit was used for detection. Odds represent the 
“relative intensity” of act-β-cat immuno-reactive bands corrected by the levels of β-catenin whole protein. 
The levels of β-actin were used to normalize protein loadings between lanes. b) LAMA-84 cells were 
treated for 24 hours with increasing concentration of celecoxib (6.25, 12.5, 25, 50 µM) before probing 
protein lysates with the antibody that recognizes the act-β-cat isoform. A HRP-conjugated secondary 
antibody produced in mouse was used for detection. Ratios of act-β-cat/β-cat “relative intensity” are 
displayed as in (f). β-actin levels were used to normalize protein loadings between lanes. 
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As stated above, the β-catenin/Tcf/Lef complex transactivates genes involved in cell 
growth or with anti-apoptotic functions. One of such target genes is the c-myc oncogene; 
thus,	  to further demonstrate that celecoxib inhibits the transcription-regulatory activity of β-
catenin, we performed quantitative real time PCR analysis of c-myc mRNA levels. Indeed, 
exposure of LAMA-84 cells to 25 µM celecoxib (for 2, 8 or 24 hours) caused a dramatic 
decrease (more evident after 8 hours) in the levels of c-myc transcripts (Figure 29), an 
effect that was confirmed also by assessing the levels of the protein (data not shown).   
It is also known that nuclear accumulation of β-catenin impairs the transcription of the 
CDKN2A gene, which encodes the p16INK4a tumor suppressor protein, with an inhibitory 
effect on cell cycle progression (23,65). Real Time PCR of CDKN2A mRNA levels assessed 
after treatment with 25 µM celecoxib (time-course of 2, 8, and 24 hours) revealed a 
significant increase of CDKN2A mRNA transcripts, although only after a 24-hours 
treatment (Figure 29).	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Figure 29. Celecoxib affects the transcription of β-catenin-target genes c-myc and CDKN2.  
 
LAMA-84 cells were treated for 2, 8 and 24 hours with 25 µM celecoxib. For each of the genes tested, 
histograms represent the ratio between mRNA levels in celecoxib-treated or 0.1% DMSO-treated (ctrl) 
groups, which were measured by means of the real-time PCR technique. Data were normalized using the 
expression of GAPDH as housekeeping gene. Values represent means of three independent experiments 
(± standard error). 
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To establish a correlation between the biochemical and biological effects of celecoxib, we 
generated a LAMA-84 parental cell line expressing a constitutively active mutant form of β-
catenin in which serine 33 is replaced by a tyrosine residue (β-catenin S33Y) that is not 
recognized by GSK-3β, thus preventing the proteolytic degradation of β-catenin (27,28). 
Then, following to treatments with celecoxib, we assessed viability and proliferation of the 
β-catenin-S33Y cell line, through concentration-response experiments using MTT and 
clonogenic assays, in comparison to parental LAMA-84 cells. As expected, cells 
expressing the degradation-resistant form of β-catenin (β-catenin-S33Y) were significantly 
more resistant than wild-type cells, to either acute (Figure 30a, upper panel) or chronic 
(Figure 30b, lower panel) exposure to celecoxib. 
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Figure 30. Cell viability of LAMA-84 
cells expressing wild-type (LAMA-84) 
or an “undegradable” mutant (LAMA-
84 β-catenin S33Y) of β-catenin.  
 
Upper panel (a) displays the result of the 
MTT assay after 24 hours treatments with 
increasing concentrations of celecoxib 
(6.25, 12.5, 25, 50, 100 µM). Lower panel 
(b) displays the result of the clonogenic 
assay after 6 days in presence of 
increasing concentrations of celecoxib 
(0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25 µM). 
Results are expressed as percentages of 
colonies counted in drug-treated groups 
as compared to 0.1% DMSO-treated 
controls. Data express averages of three 
independent experiments made in 
duplicate (± standard error). 
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3.4 Celecoxib inhibits the mammalian target of rapamycin-complex 1 
(mTORC1) while sparing complex 2 (mTORC2) 
 
Given the ability of celecoxib to re-activate GSK-3β, we tested the hypothesis that the anti-
leukaemic effects of this drug may depend, in part, on the inhibition of the mammalian 
target of rapamycin (mTOR). Indeed, it is known that GSK-3β exerts an inhibitory effect on 
mTORC1 by phosphorylating the tuberous sclerosis 2 protein (TSC2), which is endowed 
with a GTPase-activating function (32,33). In turn, such phosphorylation of TSC2 causes its 
activation and the consequent inhibition of Rheb, the small G-protein indispensable for 
mTORC1 activity. An effect on this pathway may explain, in part, the effects of celecoxib in 
CML cells since mTOR plays a critical role in the growth and survival of BCR-ABL 
transformed cells (20,31,34). 
To determine whether celecoxib inhibits mTOR activation, we evaluated the effect of the 
drug on the phosphorylation of this protein and its downstream targets.  
Immunoblots of LAMA-84 and JURL-MK1 protein extracts with anti-phospho-mTOR 
specific antibodies allowed discrimination, upon treatment with celecoxib (25 µM, given for 
2, 4, 16 and 24 hours), between phosphorylation of serine 2448 and of serine 2481, 
characteristic of, respectively, mTORC1 and mTORC2 activation. As shown in Figure 31, 
only in the LAMA-84 cell line, celecoxib was able to induce a significant decrease of serine 
2448 phosphorylation, an effect that was maximal within 4 hours of treatment. Importantly, 
phosphorylation of mTOR on serine 2481 was not affected by the treatment, suggesting 
that inhibition of mTORC1 did not cause the compensatory activation of mTORC2, usually 
observed after treatments with rapamycin and congeners. 
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celecoxib  Figure 31. Characterization of 
mTORC1 vs mTORC2 signalling in 
LAMA-84 and JURL-MK1 cell lines 
treated for 2, 4, 16 and 24 hours 
with celecoxib (25 µM).  
 
Protein lysates were blotted using 
primary polyclonal antibodies specific 
for: mTOR whole protein; mTORC1, 
identified by the phospho-serine 2448 
epitope (p-mTOR ser2448), 
mTORC2, presenting the phospho-
serine 2481 epitope (p-mTOR 
ser2481). HRP-conjugated secondary 
antibodies, produced in rabbit, were 
used for detection. Odds represent 
the “relative intensity” of phospho-
mTOR immuno-reactive bands 
corrected by the levels of the whole 
kinase. 
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In agreement with the finding of mTORC1 inhibition, celecoxib was able to reduce the 
phosphorylation of the two most important targets of mTORC1, i.e. the S6 Kinase (p70-
S6K) and eIF4E binding protein (4E-BP1). Indeed, as shown in Figure 32, in the highly 
sensitive LAMA-84 cells, celecoxib suppressed the phosphorylation of p70S6K on 
threonine 389, significantly reducing also the accumulation of hyper-phosphorylated forms 
of 4E-BP1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To confirm the ability of celecoxib to impair mTORC1 function, we measured the biological 
impact of a combined treatment (Comb.) with PP242, a catalytic inhibitor of mTOR. In 
order to do this, we analyzed the viability of LAMA-84 cells by MTT and clonogenic assays 
using concentrations of the two drugs close to their EC25 calculated in each test. 
Following to 24 hours of treatments, the MTT assay revealed that the effects of 12,5 µM 
celecoxib and 50 nM PP242 were additive (Figure 33a). Conversely, clonogenic assays 
performed in the presence of much lower concentrations of the two drugs (250 nM 
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Figure 32.  Activation of the mTORC1 down-stream targets in LAMA-84 and JURL-MK1 cell 
lines exposed to 25 µM celecoxib for 2, 4, 16 and 24 hours.  
 
Protein lysates were probed with primary polyclonal antibodies specific for: the p70S6 kinase 
(p70S6K) or its active form, phosphorylated on threonine 389 (p-p70S6K thr389); 4E-BP1 or its 
active form, phosphorylated on threonine 37 and 46 (p-4E-BP1 thr37/46).  HRP-conjugated 
secondary antibodies, produced in rabbit, were used for detection. Levels of p70S6K and 4E-BP1 
are displayed as proof of equal loadings. 
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celecoxib; 5 nM PP242) minimally increased the effect induced by each compound alone 
(Figure 33b), thus suggesting a redundant mechanism of action.	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Figure 33. Antiproliferative effects 
of celecoxib given in combination 
with a mTOR catalytic inhibitor.  
 
a) Viability of LAMA-84 cells treated 
for 24 hours with 12,5 µM celecoxib, 
50 nM PP242, or a combination 
(Comb.) of both, was determined by 
using the MTT assay. Values 
represent the mean of three 
independent experiments (celecoxib 
82,30±7,718; PP242 81,14±5,448; 
Comb. 67,98±6,907). *P ≤ 0,05, **P 
≤ 0,01, ***P ≤ 0,001 (student t-test). 
b) Clonogenic assay, dose-response 
curve of LAMA-84 cells grown for 6 
days on 80% methylcellulose (1250 
cells/well) after exposure to 250 nM 
celecoxib, 5 nM PP242, or a 
combination (Comb.) of both. 
Results are expressed as 
percentages of colonies counted in 
drug-treated groups as compared to 
0.1% DMSO-treated controls. Data 
represent the averages of three 
independent experiments made in 
duplicate (celecoxib 64,7±3,188; 
PP242 67,0±6,376; Comb. 
46,4±0,455). *P ≤ 0,05, **P ≤ 0,01, 
***P ≤ 0,001 (student t-test). 
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3.5 The activation of the AMP-activated protein kinase (AMPK) is 
involved in the effect of celecoxib 
 
It was previously shown that, in order to fully activate TSC2, GSK-3β requires an AMPK-
dependent phosphorylation of this GAP (34), thus supporting a synergistic function of the 
two kinases that are under the control of metabolic and growth factor signals (31,66). With 
this in mind, we assessed whether celecoxib treatment influences the serine/threonine 
kinase function of AMPK in order to allow a complete inhibition of mTOR via TSC2 
phosphorylation. 
Using an antibody that specifically recognizes phosphorylated threonine 172 of the alpha 
subunit of AMPK, which identify the catalytic active form of the kinase, we performed 
immunoblots on protein extracts of CML cell lines exposed to celecoxib (25 µM). As shown 
in Figure 34, only in the LAMA-84 cell line celecoxib was able to increase AMPK 
phosphorylation as soon as 15 minutes after treatment, with a maximal effect after 30 
minutes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Since AMPK can be activated either in response to a reduction in cell energy, represented 
by a relative increase of AMP over ATP concentrations, an event mediated by the tumor 
suppressor LKB1, or by the activation of the Ca2+/calmodulin-dependent kinase kinase β 
(CaMKKβ)(31,39), we investigate which of the two pathways mediates the effect of celecoxib 
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Figure 34.  Activation of AMPK in LAMA-84 cells treated with 25 µM celecoxib.  
 
LAMA-84 and JURL-MK1 cell lines were treated for 15, 30 minutes, 1 and 2 hours with celecoxib 
before probing protein lysates with polyclonal antibodies that recognize: the AMPKα subunit or its 
active form, phosphorylated on threonine 172 (p-AMPKα thr172). HRP-conjugated secondary 
antibodies, produced in rabbit, were used for detection. Odds represent the “relative intensity” of 
phospho-AMPKα immuno-reactive bands corrected by the levels of the whole protein. 
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on AMPK activation. In order to do this, we used 25 µM celecoxib to treat the LKB1-
deficient human cell line HeLa (presenting a strong methylation in the promoter of this 
gene)(39), before probing protein with antibody directed against the active form of AMPK. 
As displayed in Figure 35, also HeLa cells responded with a phosphorylation of AMPK on 
threonine 172 when challenged with celecoxib, suggesting that LKB1 is dispensable for 
this activity of the drug. Indeed, co-administration of the CaMKKβ specific inhibitor, STO-
609 (2.5ug/mL, given as a 4 hours pre-treatment) completely abolished the 
phosphorylation of AMPK (Figure 35). Next, the ability of STO609 to abolish celecoxib-
induced activation of AMPK was confirmed by immunoblots on LAMA-84 protein extracts 
(Figure 36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moreover, to assess whether CAMKKβ-induced activation of AMPK plays a role in the anti-
proliferative function of celecoxib, LAMA-84 cells were simultaneously treated with 25 µM 
celecoxib and STO-609. Although the CAMKKβ inhibitor displayed an intrinsic toxicity (a 
20% decrease in the absorbance of the MTT assay as compared to untreated controls), 
this drug still significantly reduced the effect of celecoxib when used combination with it 
(42,2% vs 53,8% absorbance compared to untreated controls; Figure 37).  
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Figure 35. Celecoxib-induced activation of 
AMPK relies on Ca2+/Calmodulin kinase 
kinase β  (CaMKKβ) function.  
 
HeLa cells, which are intrinsically devoid of the 
AMPK primary up-stream activator liver kinase 
B1 (LKB1), were treated with 25 µM celecoxib 
(for 30 minutes), the CaMKKβ inhibitor STO609 
(2,5 mg/mL, 4 hours), or a combination of both 
(Comb.; STO609 was given as a 4 hours pre-
treatment). Protein lysates were probed with anti-
phospho-AMPKα antibody as described in Figure 
34. 
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LAMA-84    Figure 36. CaMKKβ  inhibition impairs the 
effect of celecoxib also in the LAMA-84 CML 
cell line.  
 
Immunoblots of LAMA-84 protein lysates probed 
with anti-AMPK antibodies (as in Figure 34 after 
treatments with 25 µM celecoxib (30 minutes), 
STO609 (2,5 mg/mL, 4 hours) or a combination 
of both (Comb.; STO609 was given as a 4 hours 
pre-treatment).  
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To provide final demonstration of the role played by AMPK in the anti-leukaemic effect of 
celecoxib, we knocked-down the expression of this kinase using a lentivirally delivered 
microRNA (AMPKα-) that targets the α1 catalytic subunit of the protein. By this approach 
we obtained only about a 54% reduction in the expression of AMPK, compared to the 
levels of this protein in cells treated with a non-targeting sequence (SCR; inset in Figure 
38). Nevertheless, clonogenic assays on LAMA-84 SCR and AMPKα-silenced cells 
showed a clear shift to the right in the concentration-response of the cell line expressing 
lower levels of the kinase (Figure 38).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. Cell viability of LAMA-84 cells treated for 24 hours with 25 µM celecoxib, 2,5 mg/mL 
STO609.  
 
Histograms represent percentages of reduction of MTT values in drug-treated samples as compared to 
0.1% DMSO-treated groups. Values are the mean of three independent experiments (celecoxib 
42,2±0,578; STO609 80,9±0,595; Comb 53,8±0,436). *P ≤ 0,05, **P ≤ 0,01, ***P ≤ 0,001 (student t-test). 
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Figure 38. Clonogenic assay, dose-response curves of AMPK “knocked-down” (AMPKα -) vs 
“scramble-treated” (SCR) LAMA-84 cells exposed to increasing concentrations of celecoxib (0.1, 0.25, 
0.5, 1, 2.5, 5, 10, 25 µM) and grown into 80% methylcellulose.  
 
Cells were seeded at 1250 cells/well density and colonies were scored after 6 days. Results are expressed as 
percentage of the colonies counted in the 0.1% DMSO-treated group (control). Data are the averages of three 
independent experiments made in duplicate, (± standard error). In the inset, are displayed protein levels of 
AMPKα in cells exposed to lentivirally delivered scrambled (SCR) or AMPKα-targeted (AMPKα-) miRNAs. 
Immunoblots were obtained combining a polyclonal anti-AMPKα primary antibody with the HRP-conjugated 
secondary antibody produced in rabbit. Odds represent the “relative intensity” of AMPK immune-reactive 
bands corrected by the levels of β-actin used for loading normalization. 
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As proof-of-principle that AMPK is the most upstream effector of celecoxib-induced anti-
leukaemic pathway, immunoblots on SCR and AMPKα-silenced LAMA-84 cell lysates 
demonstrated that a reduced expression of AMPK abrogates the effect of 25 µM celecoxib 
on the down-regulation of β-catenin (Figure 39). 
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Figure 39. Expression of β-catenin protein in AMPKα - vs SCR LAMA 84 cells exposed to 25 µM 
of celecoxib for 24 hours.  
 
Immunoblots of protein lysates were performed combining a monoclonal anti-β-catenin primary 
antibody and the HRP-conjugated secondary antibody produced in mouse. Odds represents the 
“relative intensity” of -β-catenin immune-reactive bands corrected by the levels of β-actin, used for 
loading normalization. 
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3.6 Potential impact of celecoxib on CML-targeting therapies  
 
Previous studies demonstrated that treatment of CML cells with tyrosine-kinase inhibitors 
(TKI, e.g. imatinib), causes the activation of the autophagic response, and that process is 
detrimental for the therapeutic outcome (44). Thus, we assessed the autophagic response 
in CML cell lines treated with active concentrations of celecoxib. .  
Protein lysates of cell lines cultured for 24 h in presence of 25 µM celecoxib were blotted 
with an antibody recognizing both the cytosolic (LC3-I) and autophagosomal-associated 
(LC3-II) forms of the autophagy-specific marker microtubule-associated protein 1 light 
chain 3 (LC3). Moreover, since LC3-II accumulation may be consequent not only to the 
induction of autophaghy but also to the inhibition of autophagosome brake up (44,67), we 
tracked the so-called “autophagic flux” by adding 5 µM chloroquine (CQ) to treatments, in 
order to block lysome-dependent digestion of the vacuoles. As shown in Figure 40, the 
difference in the LC-I/II ratio in cells exposed to celecoxib or to vehicle (0.1 % DMSO) was 
negligible, while co-treatments with CQ revealed that celecoxib did not increase the levels 
of LC3-II generated by exposure to the lysomotropic agent alone. Of note, celecoxib-
sensitive (LAMA-84) and celecoxib-resistant cells (JURL-MK1) gave similar results in this 
assay (Figure 40). 
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Figure 40. The effect of celecoxib on 
CML cell autophagy.  
 
Evaluation of the “autophagic flux” of 
LAMA-84 and JURL-MK1 treated with 25 
µM celecoxib, 5 µM chloroquine (CQ), or 
a combination of both (Comb.; CQ was 
given as 1 hour pre-treatment). After 24 
hours of incubation with drugs, protein 
lysates were probed with the anti-LC3B 
primary antibody in order to discriminate 
the unmodified protein (LC3I) from its 
phosphatydylethanolamine-conjugate 
(LC3I), used as marker of active 
autophagy (see the results). A HRP-
conjugated secondary antibody, 
produced in rabbit, was used for 
detection. Odds (LC3II/LC3I ratio) 
represent the “relative intensity” of LC3II 
immune-reactive bands corrected by the 
levels of unmodified LC3B. Levels of β-
actin are shown as proof of equal 
loadings. 
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On the other hand, visualization of autophagosomes by confocal microscopy of CML cell 
lines stained with a fluorescently-labelled anti-LC3 antibody demonstrated that celecoxib 
caused, at least in the LAMA-84 cell model, a modest increase in the percentage of cells 
displaying five or more LC3-positive vacuoles as compared to controls (0.1 % DMSO) and 
CQ-treated groups (Figure 41). Nevertheless, the effect of celecoxib was not potentiated 
by co-administration of CQ, suggesting that these drugs may share the inhibitory function 
on latest stages of autophagy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Scoring of “autophagic” cells by the presence of LC3B-positive cytosolic vesicles.  
 
LAMA-84 or JURL-MK1 cells were treated for 24 hours as described for Figure 40. Histograms 
represent percentages of cells presenting at least 5 cytosolic vesicles positively stained by the anti-
LC3 antibody. 0.1 % DMSO-treated cells were used as controls (ctrl). Values are the means of three 
independent experiments (± standard error). *P ≤ 0,05, **P ≤ 0,01, ***P ≤ 0,001 (student t-test). 
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Although of a limited entity, the biological impact of celecoxib-induced autophagy was 
evaluated through clonogenic assays. Co-treatment of LAMA-84 or JURL-MK1, with 
celecoxib and CQ, demonstrated that there was no further decrease in the number of 
colonies compared to that of cells treated with celecoxib alone (using sub-optimal 
concentrations of the drug, close to its EC25 calculated for each cell line) (Figure 42). 
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Figure 42. Clonogenic assay, of LAMA-84 and JURL-MK1 cell lines cultured for 6 days on 80% 
methylcellulose after exposure to celecoxib, CQ (5µM), or a combination of both (Comb.).  
 
Celecoxib was administered for 6 days at concentrations near the EC25, as previously calculated 
through clonogenic assays (250 nM for LAMA-84; 3 µM for JURL-MK1). Results are expressed as 
percentages of the colonies counted in 0.1% DMSO-treated control groups. Data are the averages of 
three independent experiments made in duplicate (± standard error). *P ≤ 0,05, **P ≤ 0,01, ***P ≤ 0,001 
(student t-test). 
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Considering the negative effect of autophagy induction for the therapeutic effects of 
imatinib and the potential inhibition of this process caused by celecoxib, we tested the 
effect of the two drugs, given in combination, on the clonogenicity of CML cell lines. As 
clearly shown in Figure 43 (upper panel), in LAMA-84 cell line, sub-optimal concentrations 
of celecoxib (250 nM) and imanitinib (10 nM), both close to the EC25 calculated through 
clonogenic assays, have an inhibitory effect on the formation of colonies, at least of 
additive nature. Although less evident, also in JURL-MK1 cells was observed a 
potentiation of the effect caused by imatinib when adding celecoxib at concentrations 
close to their EC25 calculated for this cell line (respectively 20 nM for imatnib, and 3 µM 
for celecoxib) (Figure 43, lower panel). 
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Figure 43. Celecoxib potentiates the anti-leukaemic effect of imatinib on CML cell lines.  
 
Concentrations near the EC25 of celecoxib (see Figure 42) or of imatinib (10 nM for LAMA-84; 20 nM 
for JURL-MK1) were chosen for 6 days on the base of clonogenic assays previously performed. Drugs 
were administered alone or in combination (Comb.). Results are expressed as the percentages of the 
colonies counted in 0.1% DMSO-treated control groups. Values are the means of three independent 
experiments made in duplicate (± standard error). *P ≤ 0,05, **P ≤ 0,01, ***P ≤ 0,001  (student t-test). 
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4. Discussion 
 
Beyond their use as anti-inflammatory drugs, inhibitors of cyclooxigenase 2 (COXIB, and 
specifically celecoxib) were proposed as possible therapy for solid cancers, and 
specifically in the management of colon cancers (48,55). This type of application found its 
rationale on the demonstrated ability of COXIB to selectively reduce the production of pro-
flogistic arachidonic acid derivatives (prostaglandins, prostacyclins and leucotriens), which 
sustain inflammation as the pathogenic mechanism of cellular transformation in a large 
bowel affected by chronic colitis. Previous studies also demonstrated that over-expression 
of COX-2 in tumor cells enables various cancer-promoting effects, such as the over-
expression of pro-angiogenic factors (VEGF, IL6, IL8), the activation of metalloproteases 
(MMP1, MMP2) and the resistance to apoptosis inducing stimuli, thus establishing a 
possible correlation between COX-2 activity and the impairment of apoptosis that 
characterizes many types of cancer (50,51). 
Nevertheless, only celecoxib, amongst COXIBs, demonstrated this ability to impair cancer 
proliferation, including those tumor cells that do not express the COX-2 enzyme (53,54).  
This opened the road to several studies attempting to identify alternative molecular 
mechanisms underlying the anti-cancer function of celecoxib.  
Moving into this direction, we tested the ability of celecoxib to impair proliferation also of 
non-solid cancers, by studying the response of chromosome Philadelphia-positive (Ph+) 
Chronic Myelogenous Leukaemia cells bearing the 210 kDa isoform of the BCR-ABL 
oncogene, both in vitro and in vivo settings. Moreover, we also worked on defining the 
molecular mechanism of action of celecoxib.  
In order to characterize this response, we evaluated the impact of celecoxib on cell 
viability and its mechanism of action by using three human cell lines, K562, LAMA-84 and 
JURL-MK1. MTT assays evidenced the ability of celecoxib to impair cell proliferation in a 
concentration-dependent manner, identifying in the LAMA-84 cell line the most sensitive to 
the anti-proliferative action of celecoxib (EC50 23,8 µM) (Figure 15a). Moreover, these 
data revealed that celecoxib induces a cytostatic rather than a cytotoxic effect, at least at 
concentrations below 25 µM, since MTT absorbance of celecoxib-treated cells were 
inferior to those recorded in control groups, without reaching levels smaller of the “zero” 
time-point (which corresponds to the number of cells at the moment of treatments with 
drugs; Figure 15a). 
The anti-proliferative effects of celecoxib appeared also irreversible and time-dependent 
considering that the inhibition of cell growth caused by a single administration of the drug 
was more evident by increasing the length of exposure; indeed, the EC50 calculated six 
days after a single treatment, was consistently reduced (8,2 µM as calculated for LAMA84 
and 23,8 µM for JURL-MK1) (Figure 15b). 
In order to better understand the events underlying the anti-proliferative effect induced by 
celecoxib, we used the most responsive cell line, LAMA-84, to profile the cell cycle 
distribution. Thus, we established that after 24 hours in presence of celecoxib (25 µM) 
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most of the cells gathered in the G1 phase of the cell cycle, with a contemporary depletion 
in the S and, more evidently, in the G2 phases. Moreover, this treatment caused the 
emergence of apoptotic “bodies” identified as a SubG1 peak in the histogram that 
illustrates the distribution of single-cell DNA content. These data, which were also 
corroborated by the results of the trypan blue exclusion test and by microscopic counting 
of apoptotic nuclei, substantially confirmed previous reports on the effects of celecoxib on 
BCR-ABL-independent leukaemic cell lines (Jurkat, HL60, U937), which revealed a dose- 
and time-dependent inhibition of cell growth (with a G1-block of the cell cycle), and 
induction of apoptosis (48) (Figures 16, 17, 18). 
Intriguingly, western blot analysis of COX-2 expression together with a comparison of 
COXIB (rofecoxib) and non-COXIB (di-methyl-celecoxib) analogues in assays evaluating 
their anti-proliferative potential, provided a strong evidence that celecoxib exerts its anti-
leukaemic function in a COX-2-independent manner (Figures 20, 21). This is in agreement 
with the observations of other groups showing very similar growth inhibition patterns for 
celecoxib in COX-2 (+/+), (+/−) and (−/−) mouse embryo fibroblast and also in COX-2 
negative hematopoietic cell lines, including K562 (49,52,68). 
The most cited argument against the specificity of these anti-proliferative, COX-2-
independent effects, of celecoxib is the need of very high concentrations, around 100 µM, 
of this drug. To this regard, we were able to obtain a substantial decrease in cell 
proliferation and viability already after 24h in presence of only 25 µM celecoxib while, an 
increase in the length of exposure to this drug, allows the use of even lower 
concentrations in order to achieve similar results. Furthermore, clonogenic assays were 
useful to demonstrate that celecoxib may be active even at concentration in the lower 
micromolar range, with an EC50 of 500 nM, as calculated using the LAMA-84 cell lines 
(Figure 22). These data are of great importance since it has been demonstrated that, in 
mice, plasmatic concentrations as high as 45 µM are well tolerated in vivo. Moreover, due 
to the lipophilic nature of celecoxib, this drug is concentrated three to four times more in 
bone marrow, where leukaemogenesis occurs, than in plasma; therefore, a concentration 
of 25 µM celecoxib in the hematopoietic compartment can be achieved using a dose of 
950 mg, not to far from the daily dose commonly used in the treatment of Familial 
Adenomatous Polyposis (800 mg, divided in two administrations). 
Another important aspect of innovation of the present work is the characterization of the 
molecular pathways involved in the effects of celecoxib onto CML blasts. Indeed, we 
demonstrated, by biochemical and genetic approaches, that β-catenin down-regulation is 
pivotal in the anti-leukaemic effect evoked by celecoxib, mainly relying on de-repression 
GSK-3β (Figures 23-30). Moreover, since BCR-ABL normally inhibits GSK-3β by an Akt-
dependent phosphorylation of its ser-9 residue, our data demonstrate that celecoxib 
interferes directly with BCR-ABL oncogenic pathways. This may have important 
implications in the cure of CML patients since several groups have demonstrated that the 
Wnt/β-catenin/Tcf-Lef pathway is fundamental in maintaining the self-renewal capacity of 
LSCs. Indeed, its becoming clear that the Wnt/β-catenin/Tcf-Lef pathway is aberrantly 
activated in CML blasts during the chronic phase, when it specifically fuels the LSCs 
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towards excessive self-renewal, and, eventually, later on, toward the blast crisis evolution 
of the disease (14,17,18). Moreover, Heidel et al hypothesized that inhibition of canonical Wnt 
signaling hampers the resistance to imatinib of CML stem cells, thereby maximizing the 
therapeutic outome of a conjunct treatment with imatinib. As regards these aspects, recent 
works demonstrated that, independently of Wnt function, BCR-ABL tyrosine kinase activity 
enables β-catenin-driven transcription, by both inhibiting its GSK-3β-dependent 
degradation and facilitating the interaction with Tcf/Lef transcription factors (directly 
phosphorylating of β-catenin) (19).  
According to evidence in the literature (20), we found that celecoxib-induced restoration of 
GSK-3β, besides the impairment of the β-catenin/Tcf/Lef axis, causes the selective 
inhibition of mTORC1 assembling without a compensatory increase of mTORC2 (Figures 
31, 32). Agreeing with this data, we observed a paradoxical but transitory increase in Akt 
phosphorylation on serine 473 following to treatments with celecoxib (data no shown), 
which can be explained with the removal of the feedback inhibition on the PI3K-Akt 
pathway normally exerted by mTORC1 (69). Moreover, as regards the inhibition of cell 
proliferation, we demonstrated that the effects of celecoxib and PP242, an inhibitor of 
mTOR catalytic function, are not additive, suggesting a redundant mechanism of action 
(Figure 33).  
Interestingly, previous studies provided evidence that S6K exerts a negative control on 
GSK-3β (32), thereby contributing to the oncogenic events that increase β-catenin levels. 
On the other hand, according to our data, celecoxib-induced abrogation of mTORC1 may 
be either the consequence of GSK-3β restoration or its cause. To this regard, the 
demonstration that celecoxib is able to rapidly (within minutes) activate AMPK (Figure 34) 
seems to suggest that the consequent inhibition of mTORC1 (66,70) remains upstream of 
GSK-3β restoration. At the same time, by knocking-down its expression, we demonstrated 
that AMPK is required for both β-catenin down-regulation and the antileukaemic effects of 
celecoxib (Figures 38, 39), suggesting that the activation of the serine/threonine kinase 
occurs very upstream in the cascade of events triggered by this drug. 
Although, the demonstration that celecoxib causes AMPK phosphorylation in a CaMKKβ-
dependent manner (Figures 35-37) implies that the immediate target of this COXIB has 
the capacity to influence intracellular Ca2+ concentrations. These data are in partial 
agreement with the work of Pyrko et al. (58,71), which demonstrates that celecoxib is able to 
induce the release of Ca2+ from endoplasmic reticulum (ER) stores, although, in our model, 
this event is not associated to the activation of ER stress response (data not shown).  
Also in favour of a possible use in the therapy of CML, we demonstrated that celecoxib 
does not activate autophagy (Figure 40-42), conversely to what described for TKI (44,72). 
More suggestively, serum and amino acid deprivation, which potently activates cell 
autophagy, was able to potentiate the antiproliferative response to celecoxib (data not 
shown), while co-administration of this COXIB with very low concentrations of imatinib 
(close to the EC25 calculated for each compound) display an inhibitory effect on cell 
proliferation that was at least of additive nature (Figure 43). 
Of importance, thanks to a partnership with Dr. Bruno Calabretta’s lab (Kimmel Cancer 
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Center, Thomas Jefferson University, Philadelphia, USA), we verified the antiproliferative 
function of celecoxib on CML blasts isolated from three different patients but not on CD34+ 
hematopoietic progenitors, a result that strongly sustain the specificity of the action 
exerted by this COXIB on leukaemic cells (data not shown).  
Finally, the conserved antiproliferative response to celecoxib, dimethyl-celecoxib, but not 
to indomethacine (an inhibitor of both COX-1 and COX-2), observed by Dr Calabretta’s 
group in another BCR-ABL-dependent leukemia model, the acute lymphocytic leukaemia 
(ALL) cell line named BV173K, makes wider the horizon of the clinical applications of 
celecoxib; moreover, its ability to abrogate the clonogenicity of BV173K cells bearing the 
TKI-resistant T315I mutant of BCR-ABL suggests that celecoxib may be used to treat 
those patients left uncovered by the standard therapy. 
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